Amgen Inc. - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Amgen Inc. Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Amgen Inc.. The Group's principal activities are to discover, develop, manufacture and market human therapeutics based on advances in cellular and molecular biology. It markets human therapeutic products in the areas of hematology, oncology and inflammation. The Group's key products include Aranesp(R) (darbepoetin alfa), EPOGEN(R) (Epoetin alfa), Neulasta(R) (pegfilgrastim), NEUPOGEN(R) (Filgrastim) and Enbrel(R) (etanercept) stimulate the production of red blood cells, for the treatment of anemia associated with chronic renal failure. Neulasta(R) and NEUPOGEN(R) selectively stimulate the production of neutrophils, one type of white blood cell, for treatment of infection in-patients undergoing myelosuppressive chemotherapy. ENBREL(R) blocks the biologic activity of tumor necrosis factor, which is used for treating patients with active rheumatoid arthritis.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report